On Friday, the Therapeutic Goods Administration under Australia’s Department of Health divulged a proposal to reschedule CBD. The reschedule would permit for specific CBD products to be vended over the counter. The Therapeutic Goods Administration has opened a public comment window that will shutter next month.
Presently, CBD preparations are positioned in Schedule 4. It is allowed for therapeutic use only if ninety eight percent of the preparation’s cannabinoid content is CBD. One suggested amendment would add to that description “except when included in Schedule 3.”
One more anticipated modification would reserve Schedule 3 for CBD preparations that: are “either plant derived, or when synthetic only comprises the (-) CBD enantiomer, have a maximum suggested daily dose that is sixty mg or less of cannabidiol and are in packs containing not more than thirty days’ supply.”
In addition to the above, the ninety eight percent rule from Schedule 4 also applies. Moreover, these products can only be vended to those who are eighteen or older in age.
The Future is Now Media Group have launched a YouTube show called The Future is Now Digest, hosted by Miguel Francis-Santiago. Together […]
April 30, 2020
PRESS RELEASE — 10,000 participants are expected to join CHAIN2020 in Hong Kong on January 15, which aims to become one of […]
December 27, 2019
In a recent report, JPMorgan analysts mentioned that Square’s lately declared investment of fifty million USD in BTC is a “strong vote […]
October 20, 2020
Supporting espousal and creating ground-breaking experiences in the digital asset domain, Mastercard recently declared the extension of its cryptocurrency program, making it […]
October 16, 2020